JOINT FILING AGREEMENT
EXHIBIT 1
The undersigned hereby agree that the statement on
Schedule 13G with respect to the common stock of CinCor Pharma, Inc. dated as of September 26, 2022 is, and any amendments
thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: September 26, 2022
|
||
|
||
|
|
|
|
By:
|
VENBIO GLOBAL STRATEGIC GP III, L.P.
|
|
|
General Partner
|
|
|
|
|
By:
|
venBio Global Strategic GP III, Ltd.
|
|
|
General Partner
|
|
By:
|
*
|
|
|
Director
|
|
|
|
|
VENBIO GLOBAL STRATEGIC GP III, L.P.
|
|
|
|
|
|
By:
|
VENBIO GLOBAL STRATEGIC GP III, LTD.
|
|
|
General Partner
|
|
|
|
|
By:
|
*
|
|
|
Director
|
|
|
|
|
VENBIO GLOBAL STRATEGIC GP III, LTD.
|
|
|
|
|
|
By:
|
*
|
|
|
Director
|
|
|
|
|
*
|
|
|
Xxxxxx Xxxxxxx
|
|
|
|
|
|
*
|
|
|
Xxxxx Xxxxxxx
|
|
|
|
|
|
*By:
|
/s/ Xxxxx Xxxxxxxx
|
|
|
Xxxxx Xxxxxxxx
|
|
|
As attorney-in-fact
|
This Agreement was executed by Xxxxx Xxxxxxxx on behalf of the individual
listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2 to the original Schedule 13G filed with the U.S. Securities and Exchange Commission on October 6, 2020.